Johnson & Johnson
NYSE:JNJDrug Manufacturers - General
-$4.59 today
- Market cap
- $656.47B
- Beta
- 0.26
- P/E (TTM)
- 26.7
- EPS (TTM)
- $8.60
- Dividend yield
- 2.28%
Volume 7.93M
Average 7.71M
JNJ Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Johnson & JohnsonNYSE: JNJ
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q3 FY2026 stock-based compensation of $357M rose 2.9% year over year, behind the +11.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 22.1% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.
Context
- Stock-based compensation amounted to 1.4% of revenue in FY2025, up 0.1 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +2.9% toward the trailing-twelve-month pace of +11.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.35B USD
- Year-over-year change
- +15.1%
- 4-year CAGR
- +4.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 1.35B | +15.1% |
| FY2024 | 2024-12-29 | 1.18B | +1.2% |
| FY2023 | 2023-12-31 | 1.16B | +2.1% |
| FY2022 | 2023-01-01 | 1.14B | +0.3% |
| FY2021 | 2022-01-02 | 1.14B | — |
Stock-Based Compensation vs competitors
How JNJ compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +11.0% is the 3rd highest of 9, against a peer median of +4.4%.
- Stock-based compensation amounts to 1.4% of revenue for JNJ, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.42B USD | +11.0% | +6.0% | 1.4% | |
| LTM Jun 2026 | $976M USD | +4.5% | +12.5% | 1.5% | |
| LTM Jun 2026 | $947M USD | +14.9% | -2.9% | 1.5% | |
| LTM Jun 2026 | $892M USD | +12.5% | — | 1.3% | |
| LTM Jun 2026 | $571M USD | -45.9% | — | 1.0% | |
| LTM Jun 2026 | $553M USD | +4.3% | +6.6% | 1.1% | |
| LTM Jun 2026 | $492M USD | -3.9% | +7.2% | 1.3% | |
| LTM Jun 2026 | $460M USD | -47.2% | +11.6% | 1.5% | |
| LTM Jun 2026 | €184M EUR | +7.6% | — | 0.4% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | £0 GBP | — | — | 0.0% | |
| Peer median (excluding JNJ) | — | +4.4% | +7.2% | 1.2% | |
Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 20.88B | 17.94B | 13.33B | 14.07B | 26.8B |
| Depreciation & Amortization | 7.39B | 6.97B | 7.49B | 7.34B | 7.5B |
| Deferred Income Tax | (2.08B) | (1.66B) | (4.19B) | (2.18B) | 1.54B |
| Stock-Based Compensation | 1.14B | 1.14B | 1.16B | 1.18B | 1.35B |
| Change in Working Capital | (4.24B) | (4.01B) | 2.51B | 1.84B | (12.72B) |
| Accounts Receivables | (2.4B) | (1.29B) | (624M) | (406M) | (1.78B) |
| Inventory | (1.25B) | (2.53B) | (1.32B) | (1.13B) | (1.45B) |
| Accounts Payables | 2.44B | 1.1B | 2.35B | 1.62B | 2.38B |
| Other Working Capital | (3.03B) | (1.29B) | 2.11B | 1.75B | (11.86B) |
| Other Non-Cash Items | 324M | 819M | 2.5B | 2.03B | 49M |
| Operating Cash Flow | 23.41B | 21.19B | 22.79B | 24.27B | 24.53B |
| Capital Expenditures | (3.65B) | (4.01B) | (4.54B) | (4.42B) | (4.83B) |
| Acquisitions (Net) | (60M) | (17.65B) | 358M | (15.15B) | (17.54B) |
| Purchases of Investments | (30.39B) | (32.38B) | (10.91B) | (1.73B) | (920M) |
| Sales of Investments | 25.01B | 41.61B | 19.39B | 2.46B | 1.66B |
| Other Investing Activities | 417M | 65M | (3.42B) | 235M | (1.96B) |
| Investing Cash Flow | (8.68B) | (12.37B) | 878M | (18.6B) | (23.59B) |
| Debt Repayment | (990M) | 7.45B | (2.73B) | 10.05B | 9.64B |
| Common Stock Issued | 0 | 0 | 4.24B | 0 | 0 |
| Common Stock Repurchased | (3.46B) | (6.04B) | (5.05B) | (2.43B) | (5.95B) |
| Dividends Paid | (11.03B) | (11.68B) | (11.77B) | (11.82B) | (12.38B) |
| Other Financing Activities | 1.43B | 1.39B | (508M) | 1.07B | 3.16B |
| Financing Cash Flow | (14.05B) | (8.87B) | (15.83B) | (3.13B) | (5.54B) |
| Effect of Forex Changes | (178M) | (312M) | (112M) | (289M) | 201M |
| Net Change in Cash | 502M | (360M) | 7.73B | 2.25B | (4.4B) |
| Free Cash Flow | 19.76B | 17.19B | 18.25B | 19.84B | 19.7B |
Johnson & Johnson
NYSE:JNJ
Intrinsic Alpha fair value
Locked
Current Price
$272.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.